RC0346

RC0346 is a preclinical-stage therapeutic candidate developed by Nanjing Regenecore Biotech (also known as Nanjing Chongyuan Biotechnology) for the treatment of autoimmune diseases. The asset is part of the company's pipeline focused on innovative biologics and immune modulation. While the specific molecular target and mechanism of action have not been publicly disclosed in high-level pipeline summaries, RC0346 is being evaluated for its potential to regulate immune responses in various autoimmune conditions. It is currently undergoing preclinical studies to assess its safety and efficacy profile for potential clinical advancement.